Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Medical devices / Surgical and interventional devices / Interventional cardiology, structural heart and electrophysiology device franchises

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Interventional cardiology, structural heart and electrophysiology device franchises

Devices sold for catheter-based and transcatheter treatment of cardiovascular disease: diagnostic and interventional catheters, guidewires, balloon and stent systems, transcatheter valve and occluder devices, electrophysiology mapping and ablation systems, and their consumables. Job is to expand and treat cardiovascular cases in the cath lab and EP suite.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
90 /100
for B2B sellers
Evidence
not sized
3 sources · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Hospitals (cath labs, structural heart programmes, EP labs) and ambulatory/office-based cardiovascular providers
Buying centre
Heart centre or interventional cardiology leadership with cath lab management, structural heart team, procurement and contracting; key opinion leaders drive brand selection
Buying triggers
  • Growth of transcatheter valve and structural heart procedures
  • Expansion of complex PCI and AF ablation case volumes
  • New device indications and trial readouts
  • Hospital strategy to build or expand cardiovascular service lines
  • Replacement of legacy EP mapping and imaging platforms
Pains
  • Long learning curves and credentialing requirements for new platforms
  • High per-procedure device cost under reimbursement pressure
  • Capacity constraints in cath labs and EP suites
  • Competitive bidding with large incumbent portfolios
Scores (1–5)
Pain intensity4
Purchasing power5
Reachability4
Growth5

How this was sized

Not sized yet

No source sizes cardiovascular intervention separately. Proxy: [6] identifies North America as 41.44% of the USD 620bn 2025 global device market and surgical/endoscopy/robotic as the largest device type at 31.00%; cardiovascular intervention is a subset of that 31% with no sourced share. Bottom-up: assume cardiovascular intervention is 20-30% of the USD 200bn 2026 surgical/interventional pool, giving USD 40bn-60bn for 2026. Arithmetic: 200bn x 20% = 40bn; 200bn x 30% = 60bn. Low confidence: the 20-30% share is an assumption; [7] and [10] note that manufacturers are directing investment toward higher-growth cardiovascular intervention categories and cite Boston Scientific's agreement to acquire Penumbra, but give no segment revenue.

Alongside it in Surgical and interventional devices

// Sell into Interventional cardiology, structural heart and electrophysiology device franchises

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.